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Introduction. Hodgkin lymphoma is a highly curable lymphoid malignancy; however treatment of a significant number of patients
remains challenging. Case Report. The authors present an unusually rapidly progressing case of refractory advanced stage classical
nodular sclerosis subtype Hodgkin lymphoma with unfavorable prognosis. A 66-year-old male patient was refractory for first-
line doxorubicin, bleomycin, vinblastin, dacarbazine (ABVD) treatment with persistent disease; therefore physicians changed
treatment for dexamethasone, cytarabine, and cisplatin (DHAP) and later ifosfamide, gemcitabine, and vinorelbine (IGEV)
regimen. Unfortunately the patient developed acute kidney and respiratory failure and died after 6 months of treatment. Current
and retrospective histological examination of the patient’s lymph node biopsy, skin lesion, and autopsy revealed the same aberrantly
expressing CD4 positive nodular sclerosis subtype Hodgkin lymphoma. Conclusion. Aberrant expression of T-cell antigens on the
Hodgkin and Reed/Sternberg cells could be associated with inferior outcome. T-cell associated antigens should be investigated
more often in patients not responding sufficiently to treatment and hence treatment should be intensified or targeted therapy
(brentuximab vedotin) should be considered.
1. Introduction
Current standard treatment of Hodgkin lymphoma (HL)
is expected to cure the majority of patients. Patients with
advanced stage disease have 5-year overall survival more
than 80% [1]. However, treatment of relapsed and primary
refractory patients still remains a challenge. Median survival
of patients relapsing after second-line, high-dose therapy and
autologous stem cell transplantation is less than 3 years [2]. In
this paper the authors present a case of a rapidly progressing
refractory HL patient and they try to provide a possible
explanation for its biological nature.
2. Case Report
In August 2013, a 66-year-old male suffering from high
blood pressure and chronic obstructive pulmonary disease
presented with symptoms of recurrent fever and generalized
lymphadenomegaly. Biopsy from the left axillary lymph
node revealed classical nodular sclerosis variant of Hodgkin
lymphoma (cNS HL). Stage IV/B disease was confirmed with
hepatic, spleen, and extranodal (pulmonary) involvement
with an unfavorable prognosis (International Prognostic
Score 5). The patient had persistent fever during treatment
with several lines of antibiotics (ciprofloxacin, levofloxacin,
moxifloxacin, and piperacillin + tazobactam) and ABVD I/1
(doxorubicin, bleomycin, vincristine, and dacarbazine).
The patient arrived to our center in October 2013
with fever and clinical symptoms of extensive pneumonia.
Inflammatory involvement in the left axillary region was
also present. As for microbiological specimens, Candida
crusei was cultured from the bronchial secretion, but hemo-
cultures and skin cultures remained negative. Endocardi-
tis was excluded with transthoracic and transesophageal
echocardiography. Cytomegalovirus and cryptococcus serol-
ogy were both negative. A vertebral magnetic resonance
imaging scan was performed due to walking impairment,
which revealed tumorous bone involvement, but showed
no evidence of infection (either abscess or osteomyelitis).
Though the patient received treatment with broad-spectrum
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Figure 1: Rapid progression of Hodgkin lymphoma with an extensive disease involving liver, spleen, bone marrow, and lung in a 66-year-old
male (a) before DHAP (dexamethasone, cytarabine, and cisplatin) and (b) after 2 cycles of DHAP.
antibiotics and antifungal agents (meropenem + moxi-
floxacin and fluconazole and then amphotericin B), fever
persisted as a symptom of progressing HL.Therefore 18FDG-
PET/CT (18fluoro-deoxy-glucose-positron emission tomog-
raphy combinedwith computed tomography) was performed
in November 2013. The scans revealed an extensive disease
with supra- and infradiaphragmatic bone marrow and extra-
nodal involvement (Figure 1(a)). As only half cycle of ABVD
was administered, we considered the patient refractory due to
his rapidlyworsening clinical condition; thereforewe decided
to change to salvage therapy.
After the first cycle of DHAP chemotherapy (dexam-
ethasone, cytarabine, and cisplatin), a significant response
was observed, the patient became afebrile, tendency of
inflammatory parameters improved, and improving overall
clinical condition was seen. Before the second cycle of DHAP
in December 2013, fever reoccurred without any known
infectious origin but chemotherapy improved his clinical
condition. A subsequent interim 18FDG-PET/CT and biopsy
of the axillary skin lesion was performed. Unfortunately,
18FDG-PET/CT showed rapid progression (Figure 1(b)) in
early January 2014.
In the meantime, histopathological analysis of the axil-
lary skin lesion biopsy was performed. The specimen was
obtained from the disseminated cutaneous lesion localized
on the left side of the thorax. Histologic findings included
perivascular infiltration by atypical cells with prominent
nuclei, large cytoplasm, altogether resembling blast-like
tumorous infiltration. Based on immunohistologic character-
istics of strong CD30 positivity, coexpression with CD3/CD4
antigens, light EMA positivity, CD20 and Alk-1 negativity,
and 15% Ki-67 proliferation rate with no apparent cells of
the Reed-Sternberg morphology, possibility of a peripheral
T-cell lymphoma was considered. It was noted, however, that
the size and quality of the biopsy were insufficient for proper
diagnosis.
Considering these results, the patient was treated with
IGEV protocol (ifosfamide, gemcitabine, and vinorelbine).
Antibody drug conjugate brentuximab vedotin was consid-
ered and was under review for approval by the insurance
company, due to CD30 positivity of the tumorous cells in
both samples. Unfortunately the patient died in January
2014, during an IGEV chemotherapy cycle from acute kidney
failure and respiratory insufficiency.
3. Autopsy Results
According to autopsy results, bronchopneumonia was
marked as direct cause of death. The autopsy revealed
enlarged, firm lymph nodes in the paraaortic, mediastinal,
retroperineal, and small pelvic regions. Lungs on both
sides were infiltrated by firm, grey nodules with an average
diameter of 2.5 cm. Hepatosplenomegaly with bone marrow
suggesting hypercellularity was also noted.
Postmortem sampling included skin lesions found on the
left thorax, axillary lymph nodes, lungs, spleen, liver, and
bone marrow. Routine haematoxylin eosin staining revealed
diffuse tumorous cell infiltration in all affected organs. The
presence of Reed-Sternberg with lacunar type morphology
was obvious, presenting with collagen bands surrounding
nodules specifically in the lungs, lobated nuclei, small lobes,
less prominent nucleoli, and wide cytoplasm.
Due to the unusually rapid progression of the disease, we
decided to perform awider range of immunostainings. As the
direct cause of death was bronchopneumonia, we performed
PAS special staining along with immunohistochemistry for
CMV antigen presence. CMV pneumonia was excluded due
to CMV antigen negativity. Naphthol-AS-D-Chloroacetate




Figure 2: CD30 positivity of the HRS cells in the skin lesion (a), sporadic CD20 positivity in the skin lesion (b), leukocyte common antigen
(LCA) negative tumorous cells in the dermis (c), PAX5/CD4 coexpression in the HRS cells from the initial axillary lymph node (d), and
unusual CD4 immunoreactivity of the HRS cells from the initial axillary lymph node (e).
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Esterase (NASD), CD3, CD4, CD20, CD30, PAX5, LCA, Ki-
67, p53, LMP-1, and Bcl-6 stainings were also performed from
the bone marrow and lymph nodes as well as the skin lesion.
Tumorous cells in these regions consequently showed
strong CD30 positivity (Figure 2(a)) with CD20 negativity
(Figure 2(b)). There was no LCA immunoreactivity amidst
the tumorous cells (Figure 2(c)). CD4 immunoreactivity,
however, was undeniably positive (Figures 2(d) and 2(e)).
A cut-off value of 10% for CD4 positivity was considered
acceptable for our immunohistochemical quantification.
Based on our histological findings, we concluded that it
was a rare form of CD4 positive Hodgkin lymphoma of the
nodular sclerosis variant, with fast progression and resistance
to conventional chemotherapy.
4. Discussion
Early identification of patients with therapy refractory HL
is crucial. Besides the role of interim 18FDG-PET/CT, there
is increasing evidence for the role of biomarkers. High
TARC (thymus and activation-regulated chemokine) level at
baseline showed poor prognosis in a multivariate model to
response to therapy at baseline evaluation [3]. Soluble CD163
antigen in the serum has also been reported to be consistent
with TARC level and response to treatment [4].
In our case, it was not possible to evaluate disease
due to its rapidly progressing nature; however, diagnosis
of HL was questioned several times. Revision of the origi-
nal FFPE (formalin fixated, paraffin-embedded) blocks was
performed. Retrospectively, both samples revealed the same
CD30 positive cNS HL, as did the autopsy; thus involvement
of anti-CD30 antibody drug conjugate brentuximab vedotin
was established [5]. Unfortunately, State Insurance grants
brentuximab vedotin individually, which takes several weeks
in Hungary.
There may be other biological markers, which could
predict the progression of an otherwise potentially curable
disease. Although HL is of B-cell origin, Hodgkin/Reed-
Sternberg (HRS) cells infrequently express B-cell mark-
ers, although T-cell marker expression is also infrequently
reported [6].WhenHRS cells aberrantly express T-cell mark-
ers, they are very rarely of T-cell origin.WhenT-cell receptors
were first analyzed on a larger cohort of specimens, only 5%
of HL cases expressed TCAs (T-cell antigens) on HRS cells.
CD2, CD3, CD4, CD5, and CD8 play an important role in T-
cell receptor signaling. It is still under debate whether TCA
expression might be induced by aberrant microenvironment
or by preventing the defective B-cell receptor expression and
signaling cascade [7]. In line, by losing B-cell phenotype,
silencing of the B-cell program may provide a rationale
for HRS cell survival, which may be contributed to TCA
expression. Other than CD3 antigen, TCAs are infrequently
investigated in routine HL cases. A recent publication has
revealed an association of the expressions of these antigens
on the surface of HRS cells with worse clinical outcome [8].
Though our case suggests the latter, it is of rapid progression
and unfavorable outcome with unusual TCA expression;
further characterization of such cases and correlation with
their unique antigen presentation has to be cleared.
A physician and a consulting pathologist may decide to
further investigate a patient’s specimen with aberrant TCAs
or cytotoxicmarkers when the patient is not responding suffi-
ciently to treatment according to interim PET/CT evaluation.
When a patients’ response is unclear (besides available bio-
logical markers such as TARC and sCD163), CD4 positivity
may contribute to a therapeutic decision to choose high-
dose therapy and autologous stem cell transplantation. Being
a relatively cheap technique, aberrantly expressed T-cell
antigens, particularly CD4, should be examined at baseline
for every nodular sclerosis subtype classical Hodgkin lym-
phoma patient. Aberrantly expressing CD4 positive nodular
sclerosis subtype classical Hodgkin lymphoma patients at
baselinemay be candidates for frontline brentuximab vedotin
administration, if verified in large clinical trials.
Competing Interests
The authors declare that they have no competing interests.
References
[1] N. Skoetz, S. Trelle, M. Rancea et al., “Effect of initial treatment
strategy on survival of patients with advanced-stage Hodgkin’s
lymphoma: a systematic review and network meta-analysis,”
The Lancet Oncology, vol. 14, no. 10, pp. 943–952, 2013.
[2] S. Horning, M. Fanale, and S. deVos, “Defining a population
of Hodgkin lymphoma patients for novel therapeutics: an
international effort,” Annals of Oncology, vol. 20, article 118,
2008.
[3] M. Sauer, A. Plu¨tschow, R. D. Jachimowicz et al., “Baseline
serum TARC levels predict therapy outcome in patients with
Hodgkin lymphoma,” American Journal of Hematology, vol. 88,
no. 2, pp. 113–115, 2013.
[4] K. Jones, F. Vari, C. Keane et al., “Serum CD163 and TARC as
disease response biomarkers in classical Hodgkin lymphoma,”
Clinical Cancer Research, vol. 19, no. 3, pp. 731–742, 2013.
[5] A. Younes, N. L. Bartlett, J. P. Leonard et al., “Brentuximab
vedotin (SGN-35) for relapsed CD30-positive lymphomas,”The
New England Journal of Medicine, vol. 363, no. 19, pp. 1812–1821,
2010.
[6] M. Mu¨schen, K. Rajewsky, A. Bra¨uninger et al., “Rare occur-
rence of classical Hodgkin’s disease as a T cell lymphoma,”
Journal of Experimental Medicine, vol. 191, no. 2, pp. 387–394,
2000.
[7] A. Tzankov, C. Bourgau, A. Kaiser et al., “Rare expression
of T-cell markers in classical Hodgkin’s lymphoma,” Modern
Pathology, vol. 18, no. 12, pp. 1542–1549, 2005.
[8] G. Venkataraman, J. Y. Song, A. Tzankov et al., “Aberrant T-cell
antigen expression in classical Hodgkin lymphoma is associated
with decreased event-free survival and overall survival,” Blood,
vol. 121, no. 10, pp. 1795–1804, 2013.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
